Peer-influenced content. Sources you trust. No registration required. This is HCN.

Blood AdvancesRole of Stem Cell Transplant in CD30+ PTCL Following Frontline Brentuximab Vedotin Plus CHP or CHOP in ECHELON-2

Even with superior frontline therapy using A+CHP, this exploratory study suggests that consolidative SCT should be considered in CD30+ peripheral T-cell lymphoma (PTCL) patients. More large-scale studies are needed, especially in DUSP22-rearranged and low International Prognostic Index ALK ALCL, to determine whether there are favorable subgroups that could be treated with A+CHP alone.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form